US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

3.70

-0.4700-11.27%

Post-market: 3.700.00000.00%19:55 EDT

Volume:46.10K

Turnover:175.97K

Market Cap:3.58M

PE:-0.02

High:4.35

Open:4.28

Low:3.50

Close:4.17

52wk High:196.80

52wk Low:3.25

Shares:968.60K

Float Shares:697.36K

Volume Ratio:2.15

T/O Rate:6.61%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-190.7554

EPS(LYR):-1,128.6039

ROE:-2095.51%

ROA:-85.59%

PB:-1.78

PE(LYR):0.00

Loading ...

Overview Company News Filings

Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary

Super League FY2025 net loss widens 24.51% to $20.7 million; revenue drops 29.91% to $11.3 million

Press Release: Super League Reports Fourth Quarter and Full Year 2025 Financial Results, Completes Business Transformation and Advances Path to Profitability

Super League Enterprise Inc expected to post a loss of $3.28 a share - Earnings Preview

Super League to buy Misfits Ads Division for USD 1.5 million and 19.99% equity stake

Press Release: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Super League to acquire Misfits Ads Division for USD 1.5 million and 19.99% equity stake

BRIEF-Super League Signs Definitive Agreement To Acquire Misfits ADS Division, Expanding Revenue And Accelerating Path To Positive Adjusted EBITDA

Super League Enterprise Inc - to Buy Misfits Ads Division From Misfits Gaming Group

THOMSON REUTERS

Super League Signs Definitive Agreement to Acquire Misfits Ads Division, Expanding Revenue and Accelerating Path to Positive Adjusted Ebitda

THOMSON REUTERS

Super League Enterprise Inc. updates financial calendar with Q4 and full-year 2025 earnings webinar

Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

Automatic Data Processing Inc Stock Moved Down by 3.21% on Feb 27: What Signal Does It Send?

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:29 PM

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Super League Enterprise Inc. Files Initial Beneficial Ownership Statement for Director Marti J. Frucci

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":3.7,"timestamp":1774641600000,"preClose":4.17,"halted":0,"volume":46103,"hourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.1127098321342925,"floatShares":697356,"shares":968600,"eps":-190.75543,"marketStatus":"Market Closed","change":-0.47,"latestTime":"03-27 16:00:00 EDT","open":4.28,"high":4.3461,"low":3.5,"amount":175972.3755994,"amplitude":0.202902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-190.75543,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.31,"preClose":4.16,"latestTime":"09:12 EDT","volume":1822,"amount":7998.0375906,"timestamp":1774617126985,"change":0.15,"changeRate":0.036058,"amplitude":0.101298},"postHourTrading":{"tag":"盘后","latestPrice":3.7,"preClose":3.7,"latestTime":"19:55 EDT","volume":335,"amount":1262.45,"timestamp":1774655759045,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.148643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":697356,"roa":"-85.59%","roe":"-2095.51%","lyrEps":-1128.603888,"volumeRatio":2.148643,"shares":968600,"dividePrice":0,"high":4.3461,"amplitude":0.202902,"preClose":4.17,"low":3.5,"week52Low":3.25,"pbRate":"-1.78","psRate":"0.31","week52High":196.8,"institutionHeld":0,"latestPrice":3.7,"eps":-190.75543,"divideRate":0,"volume":46103,"delay":0,"ttmEps":-190.75543,"open":4.28,"prevYearClose":7.326,"prevWeekClose":4.7,"prevMonthClose":3.97,"prevQuarterClose":7.326,"fiveDayClose":4.7,"twentyDayClose":3.97,"sixtyDayClose":6.7536},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"SLE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"defaultRemindTime":1774598400000,"name":null,"time":"Pre-Market","dateTimestamp":1774584000000,"actualEps":null},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3},{"market":"US","date":"2025-08-14","symbol":"SLE","fiscalQuarterEnding":"2025/06","expectedEps":-6.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-4.52},{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1762833600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-03-26","current":-0.019397,"percent":0.646481,"low":-0.738945,"twenty":-0.359366,"median":-0.271962,"eighty":-0.210302,"high":-0.044016,"avg":-0.284123,"sd":0.119248,"marketCap":3777450},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-26","current":-0.23813,"twenty":-0.359366,"median":-0.271962,"eighty":-0.210302,"marketCap":3777450}],"updateTime":1774664313429},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622179822","title":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622179822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622179822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:31","pubTimestamp":1774618272,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings SummarySuper League Enterprise Inc SLE.OQ reported a quarterly adjusted loss of $9.44 per share for the quarter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2622825603","title":"Super League FY2025 net loss widens 24.51% to $20.7 million; revenue drops 29.91% to $11.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825603","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622825603?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:31","pubTimestamp":1774611088,"startTime":"0","endTime":"0","summary":"Super League published an earnings press release reporting fourth-quarter and full-year 2025 financial results.Q4 revenue was USD 3.2 million, down 6.6%.FY revenue was USD 11.3 million, down 29.9%.Super League ended 2025 with USD 14.4 million in cash and cash equivalents and said it was debt-free, while CEO Matt Edelman said cash basis EBITDA profitability is targeted by year-end.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4R3048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4112","LU0314104364.USD","NDAQ","BK4077","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","SLE","IE00BN0W2W23.USD","BK4588"],"gpt_icon":0},{"id":"2622984825","title":"Press Release: Super League Reports Fourth Quarter and Full Year 2025 Financial Results, Completes Business Transformation and Advances Path to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2622984825","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622984825?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:30","pubTimestamp":1774611000,"startTime":"0","endTime":"0","summary":"Q4 2025 Delivers Strongest Revenue Quarter of the Year. Debt-Free Balance Sheet and $14M in Year-End Cash Enable Focus on Execution. Diversified Revenue and Shift to Scalable Offerings Support Path to Profitable Future. SANTA MONICA, March 27, 2026  --  Super League  , an audience intelligence and media activation company that generates revenue by executing interactive advertising and immersive content programs for brands seeking to reach and influence people who play video games, today released fourth quarter and full year 2025 financial results.Super League Chief Executive Officer, Matt Edelman Commented:. \"Super League is a fundamentally different company than it was a year ago. We have a stronger foundation and a clearer path to scale, positioned to help brands reach and influence one of the most valuable and under-monetized consumer segments in modern media and culture--the gamer demographic.Combined with our recently announced agreement to acquire the Misfits Ads Division, subjec","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2622076334","title":"Super League Enterprise Inc  expected to post a loss of $3.28 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622076334","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622076334?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:44","pubTimestamp":1774442649,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of $3.28 a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to  show a rise in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D1DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2621756263","title":"Super League to buy Misfits Ads Division for USD 1.5 million and 19.99% equity stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2621756263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621756263?lang=en_us&edition=fundamental","pubTime":"2026-03-21 03:12","pubTimestamp":1774033948,"startTime":"0","endTime":"0","summary":"Super League entered a definitive agreement to acquire the Misfits Ads Division from Misfits Gaming Group, with closing subject to certain conditions including Super League shareholder approval.Consideration includes USD 1.5 million in cash and 19.99% of the aggregate of Super League common shares outstanding plus shares underlying certain pre-funded warrants from the October 2025 PIPE financing.Misfits may receive additional cash and equity over the 24 months after closing if specified net revenue milestones are met.Misfits will also receive a warrant to purchase Super League common stock with an exercise price of USD 18 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8svjyD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2620276193","title":"Press Release: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276193","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276193?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950700,"startTime":"0","endTime":"0","summary":"-- Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis  --. -- Plan to submit NDA for envudeucitinib in PsO in 2H 2026 --. -- Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus  anticipated 3Q 2026 --. \"Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib's highly differentiated clinical profile,\" said Martin Babler, President and Chief Executive Officer of Alumis. \"By maximally inhibiting TYK2 to block both IL-23 and IL-17 pathways, envudeucitinib delivered comprehensive disease control with rapid onset of action, high rates of skin clearance, and meaningful symptom improvements in our Phase 3 ONWARD program that reinforce our","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","SLE","ALMS","BK4007","KOL","BK4077","BK4135"],"gpt_icon":0},{"id":"2620590253","title":"Super League to acquire Misfits Ads Division for USD 1.5 million and 19.99% equity stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620590253","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620590253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:05","pubTimestamp":1773835536,"startTime":"0","endTime":"0","summary":"Super League entered a definitive agreement to acquire the Misfits Ads Division from Misfits Gaming Group. Misfits will receive USD 1.5 million in cash and 19.99% of Super League’s fully issued and outstanding common shares plus shares underlying certain pre-funded warrants from an October 2025 PIPE financing. Misfits may receive additional cash and equity over 24 months after closing tied to specified net revenue milestones. Misfits will also receive a warrant to buy Super League common stock at an exercise price of USD 18 per share, and a Misfits board member is expected to join Super League’s board after completion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6HrWmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","BK4077","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","BK4585","SG9999014005.SGD","LU0314104364.USD","SLE","NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2620399253","title":"BRIEF-Super League Signs Definitive Agreement To Acquire Misfits ADS Division, Expanding Revenue And Accelerating Path To Positive Adjusted EBITDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2620399253","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620399253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:03","pubTimestamp":1773835425,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Signs Definitive Agreement To Acquire Misfits ADS Division, Expanding Revenue And Accelerating Path To Positive Adjusted EBITDAMarch 18 (Reuters) - Super League Enterprise Inc SLE.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABYNTRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2620258079","title":"Super League Enterprise Inc - to Buy Misfits Ads Division From Misfits Gaming Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258079?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABYNTRX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2620258048","title":"Super League Signs Definitive Agreement to Acquire Misfits Ads Division, Expanding Revenue and Accelerating Path to Positive Adjusted Ebitda","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258048?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUABYNTRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2620420408","title":"Super League Enterprise Inc. updates financial calendar with Q4 and full-year 2025 earnings webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420408","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:15","pubTimestamp":1773778532,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. updates financial calendar with Q4 and full-year 2025 earnings webinar               Super League said it will release fourth-quarter and full-year 2025 financial results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6xrX76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","NDAQ","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014039.USD","SLE","IE00BKPKM429.USD","BK4585","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4112","BK4588","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2619529024","title":"Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619529024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619529024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658860,"startTime":"0","endTime":"0","summary":"- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results -. - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 -. - New, half-life extended anti-CD-19 and Fc<GAMMA>RIIb mAb  progressing toward clinical development -. - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis  ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 -. - Oral, IL-17AA/AF inhibitor  Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end -. obexelimab for the treatment of Immunoglobulin G4-Related Disease","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0098860793.USD","BK4516","LU1668664300.SGD","LU0267386448.USD","MAA","LU1791710400.SGD","BK4139","BK4588","LU1791710582.SGD","LU0106261372.USD","LU1363072403.SGD","LU0528227936.USD","LU0158827948.USD","LU1720051108.HKD","ZBIO","LU0234570918.USD","LU2089284900.SGD","LU0971096721.USD","LU1074936037.SGD","LU1244550221.USD","LU1548497426.USD","LU0795875169.SGD","IE00BZ1G4Q59.USD","LU2357305700.SGD","SOFR","BK4504","LU1732800096.USD","LU1244550494.USD","LU1720051017.SGD","LU1989772923.USD","BK4581","LU2089283258.USD","LU0225283273.USD","LU0006306889.USD","LU1989772840.SGD","LU1732799900.SGD","LU2023251221.USD","LU2111349929.HKD","LU0882574139.USD","BK4534","IND","LU0557290698.USD","LU0912757837.SGD","LU2133065610.SGD","LU2347655156.SGD","SLE","LU0320765646.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2618966465","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966465","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966465?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:05","pubTimestamp":1773173100,"startTime":"0","endTime":"0","summary":"Initial clinical response data for AlloNK in refractory rheumatoid arthritis  expected in first half of 2026. U.S. Food and Drug Administration  interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026. Strengthened board and executive leadership with deep immunology, commercial and financial expertise. Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027. Dr. Aslan continued, \"In 2026, our focus is to advance AlloNK from an early clinical program in the deep B-cell depletion space to what could become the first therapy in this class to initiate a registrational trial in RA, the autoimmune disease with the largest refractory population. We look forward to sharing initial clinical response data and engaging with the FDA on a potential pivotal trial design in refractory RA in the first half of 2026.\". -- Prioritized refractory RA as lead indication: Recei","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CRS","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","LU0963586101.USD","R","IE00B19Z4B17.USD","RA","SLE","BK4139","BK4006","BK4077","ARTV","BK4232","LU2065731478.USD","BK4187"],"gpt_icon":0},{"id":"2618243934","title":"Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618243934","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618243934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252628/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RA","SLE","CGEM","BK4077"],"gpt_icon":0},{"id":"2617411075","title":"Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617411075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617411075?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026. Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026. Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026. WELLESLEY HILLS, Mass., March 05, 2026  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.previously treated patients with ITP is designed to evaluate safety,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","LU2463526074.USD","BK4539","IND","BK4199","ASH","ITP","SLE","CLYM","BK4139","BK4109"],"gpt_icon":0},{"id":"2614677898","title":"XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614677898","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614677898?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:30","pubTimestamp":1772227800,"startTime":"0","endTime":"0","summary":"RAMAT GAN, ISRAEL, Feb.  27, 2026  (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246813/0/en/XTL-Announces-Receipt-of-Staff-Delist-Determination-from-Nasdaq-and-Plans-to-Request-Hearing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLE","XTL","BK4077","XTLB"],"gpt_icon":0},{"id":"2614085031","title":"Automatic Data Processing Inc Stock Moved Down by 3.21% on Feb 27: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085031","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085031?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:15","pubTimestamp":1772205326,"startTime":"0","endTime":"0","summary":"• ADP's stock fell despite exceeding Q2 2026 earnings and revenue expectations.\n• PEO segment growth slowed, with lower bookings and margin compression.\n• Concerns include AI impact, valuation, insider selling, and PEO performance.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261629984-market-movers-adp-20260227","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0950375773.USD","LU1037948541.HKD","LU2506951875.HKD","BK4613","IE00BFXG0V08.USD","LU1934455194.USD","PEO","LU0965508806.USD","LU2506952170.USD","LU0823417653.USD","GB00B4QBRK32.GBP","SLE","BK4528","LU1236620834.HKD","LU1228905540.USD","BK4106","LU1196500208.SGD","BK4588","LU0965509283.SGD","TTEC","LU0345774391.USD","LU1691799644.USD","LU1934455863.HKD","LU1228905037.USD","LU2404859667.USD","LU0289941410.SGD","LU0861579265.USD","IE00B5TLWC47.USD","LU2506951958.HKD","BK4585","LU1236620750.USD","BK4130","LU0690374615.EUR","LU0823417737.USD","LU1934455277.USD","BK4226","ADP","LU1032955483.USD","LU2404859741.USD","LU0545562505.USD","LU1221951046.USD","LU0965509101.SGD","GB00B4LPDJ14.GBP","LU0690374961.EUR","LU1037948897.HKD","VEEA","IE00BYQQ9H92.USD","LU1221951129.SGD","LU0965509010.AUD","BK4023"],"gpt_icon":0},{"id":"2614030956","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 01:29 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614030956","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614030956?lang=en_us&edition=fundamental","pubTime":"2026-02-26 02:29","pubTimestamp":1772044192,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 01:29 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nAQN2LNQBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2614082639","title":"Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082639?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":"100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244522/0/en/Tempest-Announces-Interim-Results-from-Ongoing-REDEEM-1-Trial-of-TPST-2003-Preparing-for-Potential-U-S-Registrational-Study-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4006","CAR","IE0031619046.USD","BK4139","LU0963586101.USD","BK4161","IE00B7SZL793.SGD","PFS","EMD","BK4022","BK4077","SLE","IE00B19Z4B17.USD","CR","BK4230","LU2065731478.USD","TPST","IE00B66KJ199.SGD","BK4195","BK4211","BK4187"],"gpt_icon":0},{"id":"2608900968","title":"Super League Enterprise Inc. Files Initial Beneficial Ownership Statement for Director Marti J. Frucci","url":"https://stock-news.laohu8.com/highlight/detail?id=2608900968","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608900968?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:23","pubTimestamp":1770067406,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Marti J. Frucci as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5MwSDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Super League Enterprise Inc. Files Initial Beneficial Ownership Statement for Director Marti J. Frucci","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":109,"code":"91000000","status":"200"}]}}